Vicore Pharma (Nasdaq US:VCRE), a clinical-stage biopharmaceutical company focused on angiotensin II type 2 receptor agonists (ATRAGs), will present at the Pareto Securities 17th Annual Healthcare Conference at Hotel At Six in Stockholm.
The company’s CFO, Hans Jeppsson, is scheduled to present on Wednesday, September 2, 2026, from 14:25 to 14:45 CEST. Vicore’s lead program, buloxibutid, an oral ATRAG for idiopathic pulmonary fibrosis, holds FDA Orphan Drug and Fast Track designations and is being studied in the 52-week Phase 2b ASPIRE trial.
Loading...
Loading translation...
Positive
None.
Negative
None.
Market Context
The platform record shows two recent conference notices followed by -8% and -7.54% 24-hour reactions...
Analysis
The platform record shows two recent conference notices followed by -8% and -7.54% 24-hour reactions. This announcement likewise provides scheduling information rather than new data; the absence of a reported result is the principal limitation.
Key Figures
Conference edition:17th annualPresentation date:September 2, 2026Presentation time:14:25-14:45 CEST+3 more
Forum participation preceded a negative 24-hour stock reaction.
24h Move is the share-price change in the day after each event; other market factors may also have contributed.
Pattern Detected
Two recent conference-participation announcements were followed by negative 24-hour reactions of -8% and -7.54%.
Key Terms
orphan drug, fast track designation, phase 2b, ipf
4 terms
orphan drugregulatory
"received Orphan Drug and Fast Track designation"
A drug designated for an orphan disease is a medicine developed to treat a rare condition that affects only a small number of people. Regulators often give these drugs special incentives—such as reduced costs, faster review, and temporary exclusive selling rights—to encourage development, which matters to investors because those incentives can make a small market financially viable and reduce competition, much like a temporary patent on a niche product.
fast track designationregulatory
"Orphan Drug and Fast Track designation from the United States Food"
Fast track designation is a status the U.S. Food and Drug Administration grants to drugs intended to treat serious conditions and address an unmet medical need. It gives the developer more frequent communication with the FDA and can allow parts of the application to be reviewed on a rolling basis, and it may pave the way to priority review or accelerated approval. It can shorten development timelines, though it does not guarantee approval.
phase 2bmedical
"global 52-week Phase 2b ASPIRE trial in IPF"
Phase 2b is a stage in the development of a new medicine or treatment where researchers test its effectiveness and safety in a larger group of people. This step helps determine whether the treatment works well enough to move forward and if it has manageable side effects, which is important for investors because successful results can lead to potential approval and market opportunity.
ipfmedical
"Phase 2b ASPIRE trial in IPF"
Idiopathic pulmonary fibrosis (IPF) is a progressive lung disease where scar tissue builds up in the lungs for reasons doctors don't fully understand, making it harder to breathe over time. For investors, IPF matters because it represents a clear medical need and a regulated market for treatments, so progress in clinical trials, regulatory approvals, or new therapies can materially affect the value of companies working on drugs or devices for this condition—much like a new road that could open access to a previously hard-to-reach town.
STOCKHOLM, SE / ACCESS Newswire / August 26, 2026 / Vicore Pharma Holding AB (Nasdaq Stockholm:VICO)(Nasdaq US:VCRE), a clinical-stage biopharmaceutical company unlocking the potential of a novel class of drugs, angiotensin II type 2 receptor agonists (ATRAGs), today announced that the company will participate in the Pareto Securities 17th Annual Healthcare Conference in Stockholm.
Location: Hotel At Six, Stockholm, Sweden Format: Presentation and 1×1 meetings Presentation Date and Time: Wednesday, September 2, 2026, 14:25-14:45 CEST Participant: Hans Jeppsson, Chief Financial Officer
About Vicore Pharma Vicore Pharma is a clinical-stage biopharmaceutical company unlocking the potential of a new class of drugs with disease-modifying potential in respiratory and fibrotic diseases, including idiopathic pulmonary fibrosis (IPF). The company's lead program, buloxibutid, is an oral small molecule angiotensin II type 2 receptor agonist, which has received Orphan Drug and Fast Track designation from the United States Food and Drug Administration and is currently being investigated in the global 52-week Phase 2b ASPIRE trial in IPF. Vicore Pharma is publicly listed on Nasdaq Stockholm (VICO) and Nasdaq US (VCRE). www.vicorepharma.com
When will Vicore Pharma (VCRE) present at the Pareto Securities 17th Annual Healthcare Conference?
Vicore Pharma will present on Wednesday, September 2, 2026, from 14:25 to 14:45 CEST. According to Vicore Pharma, the session will take place during the Pareto Securities 17th Annual Healthcare Conference held at Hotel At Six in Stockholm, Sweden.
Who will represent Vicore Pharma (VCRE) at the Pareto Securities Healthcare Conference 2026?
Vicore Pharma will be represented by Hans Jeppsson, the company’s Chief Financial Officer. According to Vicore Pharma, he will deliver the presentation and participate in 1×1 meetings during the Pareto Securities 17th Annual Healthcare Conference in Stockholm, Sweden.
Where is the Pareto Securities 17th Annual Healthcare Conference featuring Vicore Pharma (VCRE) being held?
The conference featuring Vicore Pharma is being held at Hotel At Six in Stockholm, Sweden. According to Vicore Pharma, the company will give a presentation and hold 1×1 investor meetings at this venue on September 2, 2026.
What format will Vicore Pharma’s (VCRE) participation at the Pareto Securities Healthcare Conference take?
Vicore Pharma’s participation will include a formal presentation and 1×1 meetings. According to Vicore Pharma, the presentation is scheduled for September 2, 2026, 14:25–14:45 CEST, followed by the opportunity for individual investor or stakeholder discussions.
What is Vicore Pharma’s (VCRE) lead program buloxibutid mentioned in the conference announcement?
Buloxibutid is Vicore Pharma’s lead oral small molecule angiotensin II type 2 receptor agonist. According to Vicore Pharma, it targets idiopathic pulmonary fibrosis, has Orphan Drug and Fast Track designations from the FDA, and is being evaluated in the global 52-week Phase 2b ASPIRE trial.
What therapeutic areas is Vicore Pharma (VCRE) focusing on as a clinical-stage company?
Vicore Pharma focuses on respiratory and fibrotic diseases, including idiopathic pulmonary fibrosis (IPF). According to Vicore Pharma, the company develops a novel class of drugs called angiotensin II type 2 receptor agonists (ATRAGs) with potential disease-modifying effects in these indications.
